Active	Status	Sponsor type	Region	Phase	Filter
3 Active 4 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hari, Parameswaran
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI	Recruiting	3	1100	Canada, US	Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20	SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP	Multiple Myeloma	07/29	07/40
Jacobs, Paulette
SURPASS ET, NCT04285086: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance	Active, not recruiting	3	174	Canada, Japan, US, RoW	Ropeginterferon alfa-2b, P1101, Anagrelide	PharmaEssentia, Medpace, Inc., EPS International, Brightech International	Essential Thrombocythemia	11/24	12/25